The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non–vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH–AFNET 6) trial
Open accessAbstract
Oral anticoagulation prevents ischemic strokes in patients with atrial fibrillation (AF). Early detection of AF and subsequent initiation of oral anticoagulation help to prevent strokes in AF patients. Implanted cardiac pacemakers and defibrillators allow seamless detection of atrial high rate episodes (AHRE), but the best antithrombotic therapy in patients with AHRE is not known. RATIONALE: Stroke risk is higher in pacemaker patients with AHRE than in those without, but the available data also show that stroke risk in patients with AHRE is lower than in patients with AF. Furthermore, only a minority of patients with AHRE will develop AF, many strokes occur without a temporal relation to AHRE, and AHRE can reflect other arrhythmias than AF or artifacts. An adequately powered controlled trial of oral anticoagulation in patients with AHRE is needed. DESIGN: The Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6 ) trial tests whether oral anticoagulation with edoxaban is superior to prevent the primary efficacy outcome of stroke or cardiovascular death compared with aspirin or no antithrombotic therapy based on evidence-based indications. The primary safety outcome will be major bleeding. NOAH-AFNET 6 will randomize 3,400 patients with AHRE, but without documented AF, aged ≥65 years with at least 1 other stroke risk factor, to oral anticoagulation therapy (edoxaban) or no anticoagulation. All patients will be followed until the end of this investigator-driven, prospective, parallel-group, randomized, event-driven, double-blind, multicenter phase IIIb trial. Patients will be censored when they develop AF and offered open-label anticoagulation. The sponsor is the Atrial Fibrillation NETwork (AFNET). The trial is supported by the DZHK (German Centre for Cardiovascular Research), the BMBF (German Ministry of Education and Research), and Daiichi Sankyo Europe. CONCLUSION: NOAH-AFNET 6 will provide robust information on the effect of oral anticoagulation in patients with atrial high rate episodes detected by implanted devices.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
Chan, A.-W., Tetzlaff, J. M., Gotzsche, P. C., Altman, D. G., Mann, H., Berlin, J. A., Dickersin, K., Hrobjartsson, A., Schulz, K. F., Parulekar, W. R., et al. (2013) · BMJ · doi:10.1136/bmj.e7586 · Cited by 6,251
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62343-0 · Cited by 5,051 · cited 3×
“stroke prevention efficacy and are at least as safe as VKA,(8,9) with less intracranial hemorrhage and a 10% reduction in mortality in the pivotal trials.(10) So far, all available data that demonstrate a beneficial effect of oral anticoagulation for stroke prevention have been collected in populations with AF documen…”
BackgroundInfluentialApixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483 · cited 2×
“In summary, stroke rates in patients with AHRE are often close to the threshold for a net clinical benefit of NOAC therapy(2) and appear lower than the stroke rates found in patients with paroxysmal AF detected by ECG.(5,36,37) Also, only a minority of ischemic strokes in pacemaker patients with AHRE occur in relation…”
ResultCryptogenic stroke and underlying atrial fibrillation
Sanna, T., Diener, H.-C., Passman, R. S., Di Lazzaro, V., Bernstein, R. A., Morillo, C. A., Rymer, M. M., Thijs, V., Rogers, T., Beckers, F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313600 · Cited by 2,161
Self-citationSubclinical atrial fibrillation and the risk of stroke
Healey, J. S., Connolly, S. J., Gold, M. R., Israel, C. W., Van Gelder, I. C., Capucci, A., Lau, C. P., Fain, E., Yang, S., Bailleul, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105575 · Cited by 2,100
Mant, J., Hobbs, F. R., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G. Y., & Murray, E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61233-1 · Cited by 1,556 · cited 2×
“In summary, stroke rates in patients with AHRE are often close to the threshold for a net clinical benefit of NOAC therapy(2) and appear lower than the stroke rates found in patients with paroxysmal AF detected by ECG.(5,36,37) Also, only a minority of ischemic strokes in pacemaker patients with AHRE occur in relation…”
ResultA comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke
Mohr, J. P., Thompson, J. L. P., Lazar, R. M., Levin, B., Sacco, R. L., Furie, K. L., Kistler, J. P., Albers, G. W., Pettigrew, L. C., Adams, H. P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011258 · Cited by 1,168 · cited 1×
“Studies in other populations in the absence of AF, for example, heart failure or survivors of a stroke, had overall neutral outcomes, where slight reductions in strokewere counterbalanced by increased bleeding.(11,12) Therefore, antiplatelet therapy is recommended for secondary prevention of ischemic strokes in patien…”
BackgroundGlotzer, T. V., Daoud, E. G., Wyse, D. G., Singer, D. E., Ezekowitz, M. D., Hilker, C., Miller, C., Qi, D., & Ziegler, P. D. (2009) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.109.849638 · Cited by 879 · cited 8×
“This is in line with predictions made from trial data sets.19 Systematic ECG monitoring in stroke survivors detects silent paroxysmal AF in approximately 5% of unselected stroke patients13,20 and in up to 20% when long-term ECG monitoring is applied to patients with cryptogenic stroke.21-23 Even these prolonged ECG mo…”
BackgroundResultInfluentialGlotzer, T. V., Hellkamp, A. S., Zimmerman, J., Sweeney, M. O., Yee, R., Marinchak, R., Cook, J., Paraschos, A., Love, J., Radoslovich, G., et al. (2003) · Circulation · doi:10.1161/01.cir.0000057981.70380.45 · Cited by 750 · cited 8×
“This is in line with predictions made from trial data sets.19 Systematic ECG monitoring in stroke survivors detects silent paroxysmal AF in approximately 5% of unselected stroke patients13,20 and in up to 20% when long-term ECG monitoring is applied to patients with cryptogenic stroke.21-23 Even these prolonged ECG mo…”
BackgroundResultInfluentialTemporal relationship between subclinical atrial fibrillation and embolic events
Brambatti, M., Connolly, S. J., Gold, M. R., Morillo, C. A., Capucci, A., Muto, C., Lau, C. P., Van Gelder, I. C., Hohnloser, S. H., Carlson, M., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.007825 · Cited by 676
Graham, D. J., Reichman, M. E., Wernecke, M., Zhang, R., Southworth, M. R., Levenson, M., Sheu, T.-C., Mott, K., Goulding, M. R., Houstoun, M., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.012061 · Cited by 644
Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study
Svennberg, E., Engdahl, J., Al-Khalili, F., Friberg, L., Frykman, V., & Rosenqvist, M. (2015) · Circulation · doi:10.1161/circulationaha.114.014343 · Cited by 605
BOTTO, G. L., PADELETTI, L., SANTINI, M., CAPUCCI, A., GULIZIA, M., ZOLEZZI, F., FAVALE, S., MOLON, G., RICCI, R., BIFFI, M., et al. (2009) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2008.01320.x · Cited by 380
Daoud, E. G., Glotzer, T. V., Wyse, D. G., Ezekowitz, M. D., Hilker, C., Koehler, J., & Ziegler, P. D. (2011) · Heart Rhythm · doi:10.1016/j.hrthm.2011.04.022 · Cited by 326
Grond, M., Jauss, M., Hamann, G., Stark, E., Veltkamp, R., Nabavi, D., Horn, M., Weimar, C., Köhrmann, M., Wachter, R., et al. (2013) · Stroke · doi:10.1161/strokeaha.113.001884 · Cited by 229
Self-citationRizos, T., Güntner, J., Jenetzky, E., Marquardt, L., Reichardt, C., Becker, R., Reinhardt, R., Hepp, T., Kirchhof, P., Aleynichenko, E., et al. (2012) · Stroke · doi:10.1161/strokeaha.112.654954 · Cited by 218
Self-citationKirchhof, P., Bax, J., Blomstrom-Lundquist, C., Calkins, H., Camm, A. J., Cappato, R., Cosio, F., Crijns, H., Diener, H.-C., Goette, A., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp235 · Cited by 202 · cited 2×
“Even these prolonged ECG monitoring techniques will miss silent AF in many patients.(19) Continuous monitoring of atrial rhythmcould close this diagnostic gap,(19) requiring implanted devices and automated or semiautomated analysis.”
BackgroundResultSelf-citationZiegler, P. D., Glotzer, T. V., Daoud, E. G., Wyse, D. G., Singer, D. E., Ezekowitz, M. D., Koehler, J. L., & Hilker, C. E. (2010) · Stroke · doi:10.1161/strokeaha.109.571455 · Cited by 173
PASSMAN, R., LEONG‐SIT, P., ANDREI, A., HUSKIN, A., TOMSON, T. T., BERNSTEIN, R., ELLIS, E., WAKS, J. W., & ZIMETBAUM, P. (2016) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.12864 · Cited by 115 · cited 1×
“Reacting to these uncertainties, several groups have proposed to evaluate intermittent oral anticoagulation in AHRE patients.(31,41) One prior study (IMPACT) did not find a benefit of intermittent oral anticoagulation compared with no anticoagulation in 2,718AHREpatients.”
Background
Cited by
Antithrombotic Therapy for Atrial Fibrillation
Lip, G. Y. H., Banerjee, A., Boriani, G., Chiang, C. E., Fargo, R., Freedman, B., Lane, D. A., Ruff, C. T., Turakhia, M., Werring, D., et al. (2018) · Chest · doi:10.1016/j.chest.2018.07.040 · Cited by 939
Self-citationAnticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes
Kirchhof, P., Toennis, T., Goette, A., Camm, A. J., Diener, H. C., Becher, N., Bertaglia, E., Blomstrom Lundqvist, C., Borlich, M., Brandes, A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303062 · Cited by 418
Self-citationBrieger, D., Amerena, J., Attia, J., Bajorek, B., Chan, K. H., Connell, C., Freedman, B., Ferguson, C., Hall, T., Haqqani, H., et al. (2018) · Heart, Lung and Circulation · doi:10.1016/j.hlc.2018.06.1043 · Cited by 327
Stroke Risk as a Function of Atrial Fibrillation Duration and CHA 2 DS 2 -VASc Score
Kaplan, R. M., Koehler, J., Ziegler, P. D., Sarkar, S., Zweibel, S., & Passman, R. S. (2019) · Circulation · doi:10.1161/circulationaha.119.041303 · Cited by 284
Noseworthy, P. A., Kaufman, E. S., Chen, L. Y., Chung, M. K., Elkind, M. S. V., Joglar, J. A., Leal, M. A., McCabe, P. J., Pokorney, S. D., Yao, X., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000740 · Cited by 171
Metadata
- Authors
- Kirchhof, P., Blank, B. F., Calvert, M., Camm, A. J., Chlouverakis, G., Diener, H.-C., Goette, A., Huening, A., Lip, G. Y. H., Simantirakis, E., & Vardas, P.
- Venue
- American Heart Journal
- Publisher
- Elsevier BV
- Published
- 2017-08
- Volume
- 190
- Pages
- 12-18
- ISSN
- 0002-8703 (ISSN-L)
- OpenAlex
- W2610740339
- Cited by
- 227
- References
- 23
- FWCI
- 19.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.